Gemini collaborates with The Giving Block and others, adds donations option Gemini has made digital asset giving more convenient for its users. 23014 Total views News
United States crypto exchange Gemini has added a way for customers to donate crypto to over 100 nonprofits worldwide via The Giving Block.
Gemini now gives customers the option to “Give Back With Crypto,” The Giving Block unveiled in a blog post on Thursday. Available charities range from human rights efforts to those seeking to provide clean water and beyond.
Some of the charitable groups available, as listed on The Giving Block’s website, include Water Wells for Africa, the GO2 Foundation for Lung Cancer, Kids in Need of Defense and many more.
by Barry Teater, NCBiotech writer February 16, 2021 .
RESEARCH TRIANGLE PARK – After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration.
The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC).
“Cosela will help change the chemotherapy experience for people who are battling ES-SCLC,” said Jack Bailey, the company’s chief executive officer. “G1 is proud to deliver Cosela to patients and their families as the first and only therapy to help protect against chemotherapy-induced myelosuppression.”
After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration.
The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC).
“Cosela will help change the chemotherapy experience for people who are battling ES-SCLC,” said Jack Bailey, the company’s chief executive officer. “G1 is proud to deliver Cosela to patients and their families as the first and only therapy to help protect against chemotherapy-induced myelosuppression.”
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
February 12, 2021 19:41 ET | Source: G1 Therapeutics G1 Therapeutics
- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with
extensive-stage small cell lung cancer being treated with chemotherapy -
- Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, and impacted anemia and the need for rescue interventions such as growth factors and red blood cell transfusions -
- G1 will host conference call Tuesday, February 16, 2021 at 8:00 a.m. ET -
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2021 (GLOBE NEWSWIRE) G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved COSELA�
Eugene J Gallagher thetimes-tribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thetimes-tribune.com Daily Mail and Mail on Sunday newspapers.